The global biopharmaceutical contract manufacturing market size is projected to grow by USD 9 billion from 2022 to 2028, registering a CAGR of 8.9 percent, according to a new report by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global biopharmaceutical contract manufacturing market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the biopharmaceutical contract manufacturing industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, service, source, organization size, and region. The global market for biopharmaceutical contract manufacturing can be segmented by product: biologics, biosimilars. In 2021, the biologics segment made up the largest share of revenue generated by the biopharmaceutical contract manufacturing market. Biopharmaceutical contract manufacturing market is further segmented by service: analytical and QC studies, fill and finish operations, packaging, process development. Based on source, the biopharmaceutical contract manufacturing market is segmented into: mammalian, microbial-based biologics/non-mammalian. The mammalian segment is estimated to account for the largest share of the global biopharmaceutical contract manufacturing market. On the basis of organization size, the biopharmaceutical contract manufacturing market also can be divided into: large enterprises, small and medium-sized enterprises (SMEs). The large enterprises segment held the largest share of the global biopharmaceutical contract manufacturing market in 2021 and is anticipated to hold its share during the forecast period. Biopharmaceutical contract manufacturing market by region is categorized into: North America, Europe, Asia-Pacific, Rest of the World.

By product:
– biologics
– biosimilars

By service:
– analytical and QC studies
– fill and finish operations
– packaging
– process development

By source:
– mammalian
– microbial-based biologics/non-mammalian

By organization size:
– large enterprises
– small and medium-sized enterprises (SMEs)

By region:
– North America
– Europe
– Asia-Pacific
– Rest of the World

The biologics market is further segmented into monoclonal antibodies (mAbs), recombinant proteins, vaccines, others. Among these, the mAbs segment was accounted for the highest revenue generator in 2021.

The report explores the recent developments and profiles of key vendors in the Global Biopharmaceutical Contract Manufacturing Market, including AbbVie, Inc., Ajinomoto Co. Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent, Inc., Emergent BioSolutions Inc., FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Pfizer Inc., Samsung Biologics Co., Ltd., Serum Institute Of India Pvt. Ltd., Thermo Fisher Scientific, Inc., WuXi Biologics, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global biopharmaceutical contract manufacturing market.
– To classify and forecast the global biopharmaceutical contract manufacturing market based on product, service, source, organization size, region.
– To identify drivers and challenges for the global biopharmaceutical contract manufacturing market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopharmaceutical contract manufacturing market.
– To identify and analyze the profile of leading players operating in the global biopharmaceutical contract manufacturing market.

Why Choose This Report
– Gain a reliable outlook of the global biopharmaceutical contract manufacturing market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.